Viyash Scientific Q2 FY27 Results: Consolidated Net Profit ₹84.65 Crore on Total Income of ₹1,000 Crore
- Earnings
- Pharmaceuticals

Viyash Scientific (NSE: VIYASH) reported consolidated total income of ₹999.72 crore and consolidated net profit of ₹84.65 crore for the quarter ended 30 Sep 2026, it said in a filing on 13 Nov 2026. Standalone total income was ₹401.39 crore and standalone net profit ₹23.36 crore for the same quarter.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹999.72 crore, up 16.6% YoY and 4.7% QoQ
- Net profit: ₹84.65 crore, up 16.1% YoY and 6.8% QoQ
- EPS: Basic ₹1.74, up 35.9% YoY and 15.2% QoQ
- Finance costs: ₹13.71 crore, down 21.7% YoY
Standalone
The company on its own, without its subsidiaries
- Total income: ₹401.39 crore, up 12.4% YoY and 9.0% QoQ
- Net profit: ₹23.36 crore, up 2.3% YoY and 11.7% QoQ
- EPS: Basic ₹0.53, flat YoY and up 10.4% QoQ
- Other income: ₹10.74 crore, down 38.0% YoY
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 999.72 | 857.76 | +16.6% | 954.67 | +4.7% | |
| Revenue from operations | 987.94 | 850.30 | +16.2% | 946.36 | +4.4% |
| Other income | 11.78 | 7.46 | +57.9% | 8.31 | +41.8% |
| 84.65 | 72.90 | +16.1% | 79.29 | +6.8% | |
| Profit before tax | 117.68 | 102.37 | +15.0% | 112.41 | +4.7% |
| Finance costs | 13.71 | 17.51 | -21.7% | 12.51 | +9.6% |
| Depreciation | 45.33 | 59.11 | -23.3% | 61.77 | -26.6% |
| Tax expense | 33.03 | 29.47 | +12.1% | 33.12 | -0.3% |
| Net profit margin | 8.47% | 8.50% | -0.03 pp | 8.31% | +0.16 pp |
| EPS, basic (₹) | 1.74 | 1.28 | +35.9% | 1.51 | +15.2% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Consolidated net profit grew more slowly than total income over the year: 16.1% against 16.6%. Profit before tax rose 15.0%, and the tax charge rose 12.1%, so the gap between the two is small.
Other income rose 57.9% to ₹11.78 crore, which is 1.2% of total income. Finance costs fell 21.7% to ₹13.71 crore, equal to 1.4% of total income. Depreciation fell 23.3% year on year to ₹45.33 crore; the filing does not give the reason for this fall.
The notes say ESOP Scheme 2026 added an incremental expense of ₹377 million, about ₹37.7 crore, to employee benefit expense in the quarter. The filing gives no exceptional items for the quarter, against ₹17.00 million in the quarter ended 30 Jun 2026.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 401.39 | 357.07 | +12.4% | 368.28 | +9.0% | |
| Revenue from operations | 390.65 | 339.75 | +15.0% | 353.69 | +10.4% |
| Other income | 10.74 | 17.32 | -38.0% | 14.59 | -26.4% |
| 23.36 | 22.84 | +2.3% | 20.92 | +11.7% | |
| Profit before tax | 31.91 | 32.67 | -2.3% | 27.89 | +14.4% |
| Finance costs | 2.17 | 4.10 | -47.1% | 1.44 | +50.7% |
| Depreciation | 36.20 | 30.90 | +17.2% | 32.41 | +11.7% |
| Tax expense | 8.55 | 9.83 | -13.0% | 6.97 | +22.7% |
| Net profit margin | 5.82% | 6.40% | -0.58 pp | 5.68% | +0.14 pp |
| EPS, basic (₹) | 0.53 | 0.53 | 0.0% | 0.48 | +10.4% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone net profit rose 2.3% YoY, while total income rose 12.4%.
Other income fell 38.0% to ₹10.74 crore, while revenue from operations rose 15.0%. Other income was 2.7% of total income. Depreciation rose 17.2% to ₹36.20 crore, and finance costs fell 47.1% to ₹2.17 crore.
Standalone net profit is ₹23.36 crore against consolidated net profit of ₹84.65 crore, a gap of ₹61.29 crore.
The company was formerly known as Sequent Scientific Limited. The composite scheme of amalgamation became effective on 16 Dec 2025, and comparatives for the quarter ended 30 Sep 2025 are restated under the pooling of interests method. The statutory auditors, SRBC & Co LLP, issued unmodified limited review reports on both sets of results.
The board approved an investment of ₹400.02 crore in the rights issue of Alivira Animal Health Limited, a wholly owned subsidiary, settled by adjustment against an intercompany loan. The group completed the acquisition of BioForLife Italia S.r.l. after the quarter ended, for a consideration of EURO 16.976 million; the filing says no impact has been given in the results for the quarter.
Inference
The filing says the board approved the results on 13 Nov 2026 and that the statutory auditors issued unmodified limited review reports. It also records a ₹400.02 crore investment in a wholly owned subsidiary, settled against an intercompany loan, and the completed BioForLife Italia acquisition.
What the filing leaves open is how the BioForLife Italia acquisition will affect future results, which the company has not stated.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
